ESC 365 - The safety and efficacy of istaroxime for PreCardiogenic Shock

HFA Premium Access

The safety and efficacy of istaroxime for PreCardiogenic Shock

Session: Late-Breaking Trials - Pharmacological treatment II

Topic: Pharmacotherapy

Speaker: Professor M. Metra (Milan, IT)

Event: Heart Failure 2022

Congress Presentation

Add to my library

About the speaker

Professor Marco Metra

IRCCS San Raffaele Scientific Institute, Milan (Italy)

148 presentations

50 followers

4 more presentations in this session

Short-term effects of dapagliflozin on peak VO2 in heart failure and reduced ejection fraction (DAPA-VO2): a randomized clinical trial

Speaker: Doctor J. Nunez Villota (Valencia, ES)

DIAMOND Trial: Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for Heart Failure with Reduced Ejection Fraction

Speaker: Professor B. Pitt (Ann Arbor, US)

EMPULSE - EMPagliflozin in patients hospitalized with acUte heart faiLure who have been StabilizEd

Speaker: Professor P. Ponikowski (Wroclaw, PL)

FIDELITY: Effect of finerenone by LVH subgroup

Speaker: Professor G. Filippatos (Athens, GR)

Access the full session

Late-Breaking Trials - Pharmacological treatment II

Speakers: Professor M. Metra, Doctor J. Nunez Villota, Professor B. Pitt, Professor P. Ponikowski, Professor G. Filippatos

About the event

Heart Failure 2022

21 May - 24 May 2022

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources